Stocks and Investing Stocks and Investing
Mon, May 8, 2023

Andrew Fein Maintained (CCCC) at Strong Buy with Decreased Target to $25 on, May 8th, 2023


Published on 2024-10-28 03:30:27 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Maintained "C4 Therapeutics, Inc." (CCCC) at Strong Buy with Decreased Target from $35 to $25 on, May 8th, 2023.

Andrew has made no other calls on CCCC in the last 4 months.



There are 3 other peers that have a rating on CCCC. Out of the 3 peers that are also analyzing CCCC, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Chi Fong of "B of A Securities" Maintained at Hold with Decreased Target to $5 on, Tuesday, March 28th, 2023


These are the ratings of the 2 analyists that currently disagree with Andrew


  • Terence Flynn of "Morgan Stanley" Maintained at Sell with Decreased Target to $5 on, Monday, February 27th, 2023
  • Eric Joseph of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $5 on, Friday, February 24th, 2023
Contributing Sources